Comparative Pharmacology
Head-to-head clinical analysis: LURASIDONE HYDROCHLORIDE versus ZYPREXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LURASIDONE HYDROCHLORIDE versus ZYPREXA.
LURASIDONE HYDROCHLORIDE vs ZYPREXA
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Lurasidone is an atypical antipsychotic that acts as a full antagonist at D2 and 5-HT2A receptors, with high affinity for 5-HT7 and 5-HT1A receptors, moderate affinity for alpha2C and alpha2A adrenergic receptors, and no appreciable affinity for H1, M1, or alpha1 receptors.
Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors, with higher affinity for 5-HT2A than D2. It also blocks histamine H1, alpha-1 adrenergic, and muscarinic M1 receptors.
Schizophrenia (FDA-approved)Bipolar depression (FDA-approved as monotherapy or adjunctive therapy with lithium or valproate)Off-label: acute mania, maintenance treatment of bipolar disorder, major depressive disorder, autism-related irritability
SchizophreniaBipolar I disorder (acute manic or mixed episodes)Bipolar maintenance therapyAgitation associated with schizophrenia and bipolar mania (intramuscular formulation)Major depressive disorder (adjunctive with fluoxetine)
40 mg orally once daily initially, titrated to 80 mg once daily; maximum 80 mg per day.
5-10 mg orally once daily; may increase by 5 mg/day at intervals of at least 1 week; maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 18 hours (range 14–24 hours), supporting once-daily dosing.
Terminal elimination half-life ~30 hours (range 21–54 h) in adults, allowing once-daily dosing; steady-state reached in ~5–7 days. Half-life prolonged in elderly, females, and hepatic impairment.
Primarily metabolized by CYP3A4; also undergoes metabolism via carbonyl reduction and N-dealkylation. Major metabolites: ID-14283 (active), ID-14326, and ID-11614.
Primarily metabolized by direct glucuronidation and oxidation via CYP1A2; minor pathways involve CYP2D6 and flavin-containing monooxygenase.
Approximately 80% of total radioactivity recovered in feces (67% as metabolites, 9% as unchanged drug) and 19% in urine (mostly metabolites); less than 1% excreted as unchanged parent in urine.
Primarily hepatic metabolism via CYP1A2 and CYP2D6; ~7% excreted unchanged in urine, ~57% in urine as metabolites, ~30% in feces (mostly metabolites).
99% bound to serum albumin and alpha-1-acid glycoprotein.
~93% bound, mainly to albumin and alpha1-acid glycoprotein.
Apparent volume of distribution (Vd/F) is approximately 6173 L (or ~88 L/kg for a 70 kg individual), indicating extensive tissue distribution.
Vd ~1000–1500 L (14–21 L/kg), indicating extensive extravascular distribution (large tissue binding).
Oral bioavailability is approximately 9–19% (mean ~12%) when taken with food (≥350 calories); absorption is increased 2–3 fold with food.
Oral: ~60% (due to first-pass metabolism); IM: 100%.
No dose adjustment required for mild to moderate impairment (CrCl ≥ 30 mL/min); not recommended for severe impairment (CrCl < 30 mL/min) due to lack of data.
No dose adjustment required for renal impairment; not removed by hemodialysis.
Mild impairment (Child-Pugh A): no adjustment. Moderate impairment (Child-Pugh B): reduce dose: initial 20 mg daily, max 80 mg daily. Severe impairment (Child-Pugh C): not recommended (no data).
Child-Pugh A or B: initiate 5 mg once daily, increase with caution. Child-Pugh C: no data.
Not FDA-approved for pediatric patients; safety and efficacy not established.
Adolescents (13-17 years): initiate 2.5-5 mg orally once daily; target 10-12.5 mg/day based on response and tolerability.
Start at lower dose (40 mg once daily); titrate slowly with monitoring for orthostatic hypotension, sedation, and QT prolongation.
Initiate at 5 mg once daily; increase cautiously; monitor for orthostatic hypotension and sedation.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Lurasidone is not approved for the treatment of patients with dementia-related psychosis.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Olanzapine is not approved for the treatment of dementia-related psychosis.
["Increased mortality in elderly patients with dementia-related psychosis","Suicidal thoughts and behaviors","Cerebrovascular adverse events (e.g., stroke) in elderly dementia patients","Neuroleptic malignant syndrome (NMS)","Tardive dyskinesia","Metabolic changes (hyperglycemia, dyslipidemia, weight gain)","Hyperprolactinemia","Leukopenia, neutropenia, and agranulocytosis","Orthostatic hypotension and syncope","Seizures","Body temperature dysregulation","Dysphagia","Cognitive and motor impairment"]
["Increased mortality in elderly patients with dementia-related psychosis","Suicidal thoughts or behaviors (monitor closely)","Neuroleptic malignant syndrome (NMS)","Tardive dyskinesia","Hyperglycemia and diabetes mellitus","Dyslipidemia","Weight gain","Orthostatic hypotension","Leukopenia/neutropenia/agranulocytosis","Seizures","Body temperature dysregulation","Dysphagia","Cognitive and motor impairment"]
["Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's wort) or strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir)","Known hypersensitivity to lurasidone or any components of the formulation"]
["Hypersensitivity to olanzapine or any component of the formulation"]
Data Pending Review
Data Pending Review
Take with food (≥350 calories). Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition increasing lurasidone exposure. High-fat meal may further increase absorption.
Grapefruit and grapefruit juice may increase olanzapine levels; avoid concurrent intake. Food does not significantly affect absorption.
Limited human data; animal studies show fetal harm at doses ≥ human therapeutic range. First trimester: potential risk of congenital malformations (neural tube defects, cardiac anomalies) based on animal studies. Second/third trimester: risk of neonatal extrapyramidal symptoms, withdrawal, or poor neonatal adaptation syndrome following late third trimester exposure.
First trimester: Limited data, no consistent association with major malformations. Second/Third trimesters: Risk of extrapyramidal symptoms and/or withdrawal symptoms in neonates after third trimester exposure, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder.
No human data; lurasidone is excreted in rat milk. M/P ratio unknown. Due to potential for adverse effects on infant development (CNS effects, weight gain), breastfeeding is not recommended during therapy.
Olanzapine is excreted in human milk; estimated infant dose is about 1.8% of maternal weight-adjusted dose. Milk-to-plasma ratio approximately 0.2. Use with caution, monitor infant for sedation, irritability, and poor feeding.
No established dose adjustments; pregnancy-induced changes in CYP3A4 and P-gp activity may reduce lurasidone exposure. Monitor clinical response and adjust dose if needed. Consider therapeutic drug monitoring if available.
No specific dosing adjustment recommended, but pharmacokinetic changes in pregnancy (increased volume of distribution, increased clearance) may require dose increases during third trimester; monitor clinical response and adjust accordingly. Postpartum dose may need reduction to pre-pregnancy level.
Category A/B
Category C
Lurasidone requires administration with food (≥350 calories) to enhance absorption by ~2-fold; avoid grapefruit/grapefruit juice. Monitor for akathisia, somnolence, and metabolic changes (minimal weight gain relative to other atypicals). Use with caution in renal impairment (CrCl ≤30 mL/min: max dose 40 mg/day) and hepatic impairment (Child-Pugh moderate: max 40 mg/day; severe: not recommended). QT prolongation risk, especially in hypokalemia or concurrent QT-prolonging drugs. Efficacy in bipolar depression with unique receptor profile (5-HT7 antagonism).
ZYPREXA (olanzapine) is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors. Monitor for metabolic syndrome: weight gain, hyperglycemia, dyslipidemia. Avoid use in elderly patients with dementia-related psychosis due to increased mortality risk. Sedation is common; titrate dose slowly. Can prolong QTc interval; caution with other QTc-prolonging drugs. May cause orthostatic hypotension; advise patients to rise slowly. Extrapyramidal symptoms are less common than with typical antipsychotics but can occur.
Take lurasidone with food (at least 350 calories) to ensure proper absorption.Avoid grapefruit and grapefruit juice while taking this medication.May cause dizziness or drowsiness; avoid driving until you know how it affects you.Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.Report any involuntary muscle movements, restlessness, or changes in mood immediately.Limit alcohol consumption as it may increase side effects like drowsiness.
Take exactly as prescribed; do not stop abruptly.May cause drowsiness; avoid driving or operating machinery until you know how it affects you.Stand up slowly from sitting or lying down to prevent dizziness.Report any fever, stiff muscles, confusion, or irregular heartbeat immediately.Monitor weight and blood sugar regularly; report excessive thirst, hunger, or urination.Avoid alcohol and other CNS depressants.Use sun protection; may increase sensitivity to sunlight.